SEC Form 4 · accession 0001209191-17-066677
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven B Ratoff
Director
Period of report
Dec 18, 2017
Accepted (ET)
Dec 20, 2017 · 5:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 18, 2017 | M | 2,340 | $0.90 | A | 15,664 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.90 | Dec 18, 2017 | M | 2,340 | D | — | Mar 6, 2018 | Common Stock | 2,340 | 0 | D |
Explanation of responses
- F1These shares are fully vested and immediately exercisable.